Advances in recent techniques for scientific data collection in the era of big data allow for the
systematic accumulation of large quantities of data at various data-capturing sites. Similarly …

Diffuse large B cell lymphoma (DLBCL), the most common type of Non‐Hodgkin lymphoma
(NHL), comprises a heterogeneous group of diseases with different biology, clinical …

Background Diffuse large B-cell lymphoma (DLBCL) is typically treated with rituximab,
cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). However, only 60 …

In diffuse large B cell lymphoma (DLBCL), tumors belonging to the ABC but not GCB gene
expression subgroup rely upon chronic active B cell receptor signaling for viability, a …

Circulating tumor-derived DNA (ctDNA) is an emerging biomarker for many cancers, but the
limited sensitivity of current detection methods reduces its utility for diagnosing minimal …

The development of precision medicine approaches for diffuse large B cell lymphoma
(DLBCL) is confounded by its pronounced genetic, phenotypic, and clinical heterogeneity …

Profiling of circulating tumor DNA (ctDNA) in the bloodstream shows promise for
noninvasive cancer detection. Chromatin fragmentation features have previously been …

Single-cell RNA-sequencing has emerged as a powerful technique for characterizing
cellular heterogeneity, but it is currently impractical on large sample cohorts and cannot be …

Comprehensively charting the biologically causal circuits that govern the phenotypic space
of human cells has often been viewed as an insurmountable challenge. However, in the last …

Biological heterogeneity in diffuse large B cell lymphoma (DLBCL) is partly driven by cell-of-
origin subtypes and associated genomic lesions, but also by diverse cell types and cell …